Company intelligence / Profile preview
NEC Corporation
Minato-ku, Tokyo, Japannec.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting clinical trials for personalized cancer vaccines including TG4050 in collaboration with Transgene for ovarian cancer and head and neck cancer. Also developing NECVAX-NEO1, an orally delivered bacteria-based DNA vaccine targeting patient-specific tumor neoantigens[5][6].
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Personalized cancer vaccinesDNA vaccinesbacteria-based vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
TransgeneBostonGeneCEPIAGC BiologicsNagasaki UniversityCONNECT consortium
Beyond the preview
Go deeper on NEC Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEC Corporation.